After the FDA rejection of Zurzuvae in one type of depression, and the triple failure of neuro asset dalzanemdor, Sage was ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB).The company has introduced a new corporate identity and logo that reflect both its ...

A company representative said there are about 2,500 people worldwide taking Aduhelm. Biogen said it will turn its focus more to other treatments for Alzheimer’s, a fatal, mind-robbing disease.

Biogen said over the past year it looked for potential partners or external financing for Aduhelm, but the company said neither materialized. Biogen said it also considered the time and investment ...

Biogen agreed to buy Reata Pharmaceuticals for $7.3 billion, offering the company access to a drug that fits perfectly with its goals of treating both neuromuscular and rare diseases.

T his was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company ...

The Biogen Inc., headquarters is pictured on March 11, 2020, in Cambridge, Mass. Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch ...

TOKYO, Aug. 1, 2019 /PRNewswire/ -- FUJIFILM Corporation ("Fujifilm") today announced that it has completed the acquisition of Biogen (Denmark) Manufacturing ApS, a large-scale biologics ...